SEC Form 4 · accession 0001094891-16-000493
Origo Acquisition Corp · OACQ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Lindsay A Rosenwald M.D.
Officer — Co-Chairman and CEO · Director · 10% Owner
Fortress Biotech, Inc.
10% Owner
Period of report
May 20, 2016
Accepted (ET)
May 23, 2016 · 1:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001619551
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF2,F1 | May 20, 2016 | S$0 | 1,020,000 | — | D | 265,000 | I | By Fortress Biotech, Inc. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Mr. Rosenwald is the Chairman, President and Chief Executive Officer of Fortress Biotech, Inc. (formerly Coronado Biosciences, Inc.), and as such, controls the voting and disposition of such securities. Mr. Rosenwald disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that Mr. Rosenwald is the beneficial owner of these securities for puposes of Section 16 or for any other purpose.
- F2$0.00000095238 per ordinary share.